Feedback / Questions
indatuximab ravtansine (BT-062) - ImmunoGen, ADMA Biologics
Biotest: Q3 FY 2015 Results
(Biotest)
-
Nov 14, 2015 -
Anticipated final data from P1/2 trial (NCT01001442) in multiple myeloma in 2016
Anticipated P1/2 data
•
Multiple Myeloma • Oncology
http://www.biotest.com/de/en/investor_relations/news_and_publications/publications/presentations_and_analyst_call.cfm
Nov 14, 2015
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious